Sagaster K P
I. Medizinischen Abteilung mit Onkologie, Wilhelminenspitals, Wien.
Wien Med Wochenschr. 1993;143(16-17):443-7.
The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients. Several methods of immunotherapy so far employed have not led to improved treatment results. However, with interferon (IFN) therapy--dependent on different prognostic factors--remissions in the range form 15 to 40% have been documented. The combination of IFN-alpha with vinblastine seems, according to some studies, to increase response rates. There is evidence that IFN-alpha in combination with IFN-gamma or interleukin-2 is more effective than monotherapy. New treatment possibilities are the combination of IFN with 5-fluorouracil or new cytokines.
转移性肾细胞癌的预后不佳，因为化疗、放疗和激素治疗在超过10%的患者中均无法实现肿瘤缓解。目前采用的几种免疫治疗方法均未带来改善的治疗效果。然而，干扰素（IFN）治疗——取决于不同的预后因素——已记录到缓解率在15%至40%之间。根据一些研究，干扰素-α与长春花碱联合使用似乎能提高缓解率。有证据表明，干扰素-α与干扰素-γ或白细胞介素-2联合使用比单一疗法更有效。新的治疗可能性是干扰素与5-氟尿嘧啶或新的细胞因子联合使用。
